vida: extract claims from 2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap

- Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation"
+confidence: experimental
+source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed
+created: 2026-04-13
+title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+agent: vida
+scope: causal
+sourcer: Omada Health
+---
+
+# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+
+The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns.
+
+The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
+
+Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.

domains/health/uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Despite substantial clinical evidence supporting an A/B rating for GLP-1 pharmacotherapy, no formal petition has been filed and no update process is publicly announced, leaving the most powerful single policy lever for mandating coverage unused
+confidence: proven
+source: USPSTF 2018 Adult Obesity Recommendation, verified April 2026 status check
+created: 2026-04-13
+title: The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
+agent: vida
+scope: structural
+sourcer: USPSTF
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
+---
+
+# The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
+
+The USPSTF's 2018 Grade B recommendation for adult obesity covers only intensive multicomponent behavioral interventions (≥12 sessions in year 1). While the 2018 review examined pharmacotherapy, it covered only orlistat, lower-dose liraglutide, phentermine-topiramate, naltrexone-bupropion, and lorcaserin—therapeutic-dose GLP-1 agonists (Wegovy/semaglutide 2.4mg, Zepbound/tirzepatide) were entirely absent from the evidence base as they did not exist at scale. The recommendation explicitly declined to recommend pharmacotherapy due to 'data lacking about maintenance of improvement after discontinuation.' As of April 2026, this 2018 recommendation remains operative. The USPSTF website flags adult obesity as 'being updated' but the redirect points toward cardiovascular prevention (diet/physical activity), not GLP-1 pharmacotherapy. No formal petition or nomination for GLP-1 pharmacotherapy review has been publicly announced. This matters because a new USPSTF A/B recommendation covering GLP-1 pharmacotherapy would trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans—the most powerful single policy lever available, more comprehensive than any Medicaid state-by-state expansion. The clinical evidence base that could support an A/B rating (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) exists and is substantial. Yet the policy infrastructure has not caught up to the clinical evidence, and no advocacy organization has apparently filed a formal nomination to initiate the review process. This represents a striking policy gap: the most powerful available mechanism for mandating GLP-1 coverage sits unused despite strong supporting evidence.

entities/health/omada-health.md

@@ -0,0 +1,12 @@
+# Omada Health
+
+**Type:** Digital health company  
+**Focus:** Employer-sponsored chronic condition management programs  
+**Key Product:** Enhanced GLP-1 Care Track with behavioral wraparound
+
+## Overview
+Omada Health operates digital health programs for chronic condition management, primarily distributed through employer-sponsored benefits. Their Enhanced GLP-1 Care Track combines medication support with high-touch behavioral interventions including care teams, dose titration education, side effect management, nutrition guidance, exercise specialists, and access barrier navigation.
+
+## Timeline
+- **2025-01-01** — Internal analysis (n=1,124) shows 94% GLP-1 persistence at 12 weeks vs. 42-80% industry range, and 63% of discontinuers maintaining or continuing weight loss 12 months post-cessation
+- **2025-10-XX** — Presented post-discontinuation outcomes at ObesityWeek 2025 (peer-reviewed publication pending as of April 2026)

entities/health/uspstf.md

@@ -0,0 +1,15 @@
+# United States Preventive Services Task Force (USPSTF)
+
+## Overview
+Independent panel of national experts in prevention and evidence-based medicine that makes recommendations about clinical preventive services. USPSTF A/B recommendations trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans.
+
+## Key Mechanism
+USPSTF recommendations are the most powerful single policy lever for mandating coverage of preventive services in the US healthcare system. Grade A/B recommendations automatically trigger mandatory coverage requirements under the Affordable Care Act.
+
+## Timeline
+- **2018-09-18** — Published Grade B recommendation for adult obesity covering intensive multicomponent behavioral interventions (≥12 sessions in year 1); reviewed pharmacotherapy but declined to recommend due to insufficient maintenance data; therapeutic-dose GLP-1 agonists not yet available
+- **2024** — Updated children and adolescents obesity recommendation (behavioral-only, did not address adult pharmacotherapy)
+- **2026-04** — Adult obesity topic flagged as 'being updated' on website but redirect points toward cardiovascular prevention rather than GLP-1 pharmacotherapy; no formal petition for GLP-1 review publicly announced
+
+## Policy Gap
+As of April 2026, the 2018 recommendation remains operative despite substantial clinical evidence base for therapeutic-dose GLP-1 agonists (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) that could support an A/B rating. No formal nomination or petition process for GLP-1 pharmacotherapy review has been initiated.

inbox/archive/health/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md

@@ -7,9 +7,12 @@ date: 2018-09-18
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-13
 priority: high
 tags: [uspstf, glp1, policy, obesity, aca-coverage, pharmacotherapy, access-infrastructure]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md

@@ -7,9 +7,12 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-13
 priority: high
 tags: [glp1, racial-disparities, access-equity, medicaid, prescribing-disparities, health-equity]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content